Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2023
2022
2021
2020
2019
2018
2017
2016
Older
Aug 25, 2023
Notification of half-year results & investor web conference
Jul 31, 2023
Q2 2023 quarterly activity and cash flow report
Jul 27, 2023
Neuren receives US$100m for expanded DAYBUE agreement
Jul 14, 2023
Investor web conference presentation, 14 July 2023
Jul 14, 2023
Neuren and Acadia expand global partnership for trofinetide
Jun 30, 2023
Neuren completes enrolment in Phelan-McDermid Phase 2 trial
Jun 28, 2023
Neuren opens first site in US for Prader-Willi Phase 2 trial
Jun 14, 2023
Change of Director's Interest Notice
Jun 07, 2023
Neuren receives US$40m milestone payment
Jun 05, 2023
Neuren presenting at Jefferies Global Healthcare Conference
Previous
1
2
3
4
5
Next
